Answers are grounded in this paper and cite their sources.
Our study represents an important conceptual advance that CCL3 may be one of the key culprits of intestinal tissue damage in NEC patients, and blocking either CCL3, CCR4, or NF-κB may represent a novel effective immunotherapy for NEC.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: